Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Neal Shore

Showing results (111-120 of 191) with videos related to

Pageof 20
Sort By:
European Urology|August 19, 2018
Managing Nonmetastatic Castration-resistant Prostate CancerJoaquin Mateo, Karim Fizazi, Silke Gillessen, et al.
Future Oncology (London, England)|October 13, 2022
Which traits affect how long patients with advanced prostate cancer live when treated with enzalutamide?Ugo De Giorgi, Maha Hussain, Neal Shore, et al.
The Journal of Sexual Medicine|January 20, 2025
Preservation of sexual function with Optilume-a novel treatment for lower urinary tract symptoms secondary to benign prostatic hyperplasiaOlivia Copelan, Jared Moss, Sheldon Freedman, et al.
Urology|April 29, 2019
Three-year Active Surveillance Outcomes in a Contemporary Community Urology Cohort in the United StatesJeremy B Shelton, Thomas A Paivanas, Phil Buffington, et al.
Future Oncology (London, England)|October 12, 2021
Real-world outcomes of second novel hormonal therapy or radium-223 following first novel hormonal therapy for mCRPCOliver Sartor, Daniel George, Bertrand Tombal, et al.
The New England Journal of Medicine|February 15, 2019
Darolutamide in Nonmetastatic, Castration-Resistant Prostate CancerKarim Fizazi, Neal Shore, Teuvo L Tammela, et al.
European Urology|February 27, 2025
Effects of Enzalutamide on the Sexual Activity of Patients with Biochemically Recurrent Prostate Cancer: A Post Hoc Analysis of Patient-reported Outcomes in the EMBARK StudyStephen J Freedland, John P Mulhall, Martin Gleave, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 18, 2013
Denosumab and bone metastasis-free survival in men with nonmetastatic castration-resistant prostate cancer: exploratory analyses by baseline prostate-specific antigen doubling timeMatthew R Smith, Fred Saad, Stephane Oudard, et al.
European Urology Oncology|August 19, 2022
Erratum to "Phase 3 Randomized Controlled Trial of Androgen Deprivation Therapy with or Without Docetaxel in High-risk Biochemically Recurrent Prostate Cancer After Surgery (TAX3503)" [Eur Urol Oncol 2021;4:543-52]Michael J Morris, Jose Mauricio Mota, Kristine Lacuna, et al.
European Urology Oncology|May 22, 2021
Phase 3 Randomized Controlled Trial of Androgen Deprivation Therapy with or Without Docetaxel in High-risk Biochemically Recurrent Prostate Cancer After Surgery (TAX3503)Michael J Morris, Jose Mauricio Mota, Kristine Lacuna, et al.
Pageof 20

Showing results (111-120 of 191) with videos related to

Sort By:
Pageof 20
European Urology|August 19, 2018
Managing Nonmetastatic Castration-resistant Prostate CancerJoaquin Mateo, Karim Fizazi, Silke Gillessen, et al.
Future Oncology (London, England)|October 13, 2022
Which traits affect how long patients with advanced prostate cancer live when treated with enzalutamide?Ugo De Giorgi, Maha Hussain, Neal Shore, et al.
The Journal of Sexual Medicine|January 20, 2025
Preservation of sexual function with Optilume-a novel treatment for lower urinary tract symptoms secondary to benign prostatic hyperplasiaOlivia Copelan, Jared Moss, Sheldon Freedman, et al.
Urology|April 29, 2019
Three-year Active Surveillance Outcomes in a Contemporary Community Urology Cohort in the United StatesJeremy B Shelton, Thomas A Paivanas, Phil Buffington, et al.
Future Oncology (London, England)|October 12, 2021
Real-world outcomes of second novel hormonal therapy or radium-223 following first novel hormonal therapy for mCRPCOliver Sartor, Daniel George, Bertrand Tombal, et al.
The New England Journal of Medicine|February 15, 2019
Darolutamide in Nonmetastatic, Castration-Resistant Prostate CancerKarim Fizazi, Neal Shore, Teuvo L Tammela, et al.
European Urology|February 27, 2025
Effects of Enzalutamide on the Sexual Activity of Patients with Biochemically Recurrent Prostate Cancer: A Post Hoc Analysis of Patient-reported Outcomes in the EMBARK StudyStephen J Freedland, John P Mulhall, Martin Gleave, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 18, 2013
Denosumab and bone metastasis-free survival in men with nonmetastatic castration-resistant prostate cancer: exploratory analyses by baseline prostate-specific antigen doubling timeMatthew R Smith, Fred Saad, Stephane Oudard, et al.
European Urology Oncology|August 19, 2022
Erratum to "Phase 3 Randomized Controlled Trial of Androgen Deprivation Therapy with or Without Docetaxel in High-risk Biochemically Recurrent Prostate Cancer After Surgery (TAX3503)" [Eur Urol Oncol 2021;4:543-52]Michael J Morris, Jose Mauricio Mota, Kristine Lacuna, et al.
European Urology Oncology|May 22, 2021
Phase 3 Randomized Controlled Trial of Androgen Deprivation Therapy with or Without Docetaxel in High-risk Biochemically Recurrent Prostate Cancer After Surgery (TAX3503)Michael J Morris, Jose Mauricio Mota, Kristine Lacuna, et al.
Pageof 20